Cynthia Pamela Alatorre Fernández

Dr. Cynthia Pamela Alatorre Fernández

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2023 in The Journal of Infection in Developing Countries
Verified
Journal Article
Open access
PDF file
CFCynthia Pamela Alatorre Fernández
Cynthia Pamela Alatorre Fernández
PJPatricia Cornejo Juarez
Patricia Cornejo Juarez
CVConsuelo Velázquez-Acosta
Consuelo Velázquez-Acosta
PVPatricia Volkow
Patricia Volkow
Introduction: Oncologic patients can have severe infections due to Aeromonas. This study aims to investigate the clinical characteristics and outcomes of cancer patients with bloodstream infections (BSI) caused by Aeromonas. Methodology: We included patients with bacteremia caused by Aeromonas species from 2011 to 2018. Results: Seventy-five BSI events in the same number of patients were identified. Forty patients were men (53.3%); the mean age was 49 years (IQR 28-61). A. caviae was the most frequent isolate (n = 29, 38.6%), followed by A. hydrophila (n = 23, 30.6%), A. sobria (n = 15, 20%), and A. veronii (n = 8, 10.6%). The most frequent underlying diagnosis was hematologic malignancy (n = 33, 44%), followed by breast cancer (n = 12, 16%) and gastrointestinal tract cancer (n = 8, 10.6%). The most frequent type of bacteremia was CRBSI in 32 cases (42.6%), followed by mucosal barrier injury-laboratory confirmed BSI (n = 20, 26.7%). Sixteen (26.2%) were hospital-acquired BSI. Attributable mortality occurred in 11 patients (14.6%). In univariate analysis A. hydrophila bacteremia, liver failure, skin/soft tissue infection, septic shock, inappropriate antimicrobial treatment, and relapse or cancer progression were associated with 30-day mortality. In multivariate analysis, only septic shock, inappropriate antimicrobial treatment, and relapse or cancer progression were associated with 30-day mortality. Conclusions: Aeromonas species should be considered one of the causative pathogens of healthcare-associated bacteremia, especially in immunocompromised patients. In addition, it can be associated with high fatality, particularly in patients with severe clinical infections.

12 December 2022 in Clinical and Experimental Medicine
Verified
Journal Article
Closed access
AMAlexandra Martin-Onraet
Alexandra Martin-Onraet
CBCorazón Barrientos-Flores
Corazón Barrientos-Flores
DVDiana Vilar-Compte
Diana Vilar-Compte
Carolina Perez-JimenezCarolina Perez-Jimenez
Carolina Perez-Jimenez
CFCynthia Pamela Alatorre Fernández
Cynthia Pamela Alatorre Fernández

30 January 2026 in Viruses
Verified
Journal Article
Open access
PDF file
PVPatricia Volkow
Patricia Volkow
MVMarco Villanueva-Reza
Marco Villanueva-Reza
SÁSantiago Ávila-Ríos
Santiago Ávila-Ríos
EMEnrique Mendoza-Ramirez
Enrique Mendoza-Ramirez
AVAmérica Citlali Vera-Jimenez
América Citlali Vera-Jimenez
JVJoel Armando Vazquez-Perez
Joel Armando Vazquez-Perez
Immunocompromised patients, including those with advanced HIV infection, hematologic malignancies treated with anti-CD20 monoclonal antibodies, or combined immunodeficiencies, are at increased risk of persistent SARS-CoV-2 infection. While long-term viral shedding has been described in these patients, the extent and nature of intra-host viral evolution during long-term infection remain insufficiently documented. In this study, we report longitudinal genomic analyses of SARS-CoV-2 from three immunocompromised individuals with persistent COVID-19: (i) a female patient with follicular lymphoma receiving bendamustine-rituximab therapy with 9 months of persistence, (ii) a male patient with advanced HIV infection following prolonged antiretroviral therapy interruption with 10 months of persistence, and (iii) a female patient with Good’s Syndrome characterized by combined humoral and cellular immune deficiency with apparently four years of persistence. Replication-competent virus was detected over extended periods. Sequential whole-genome sequencing revealed the gradual accumulation of non-synonymous mutations across multiple viral genes, consistent with ongoing viral replication and intra-host diversification in the absence of effective immune control. Although based on a limited number of cases, these findings provide descriptive evidence that persistent SARS-CoV-2 infection in immunocompromised hosts can be associated with sustained viral evolution. This work highlights the importance of continued virological monitoring in selected patients with prolonged infection and contributes to the understanding of SARS-CoV-2 dynamics in settings of impaired immunity.

25 June 2024 in Indian Journal of Medical Microbiology
Verified
Journal Article
Closed access
SPSarai Pineda-Benítez
Sarai Pineda-Benítez
BIBEDA DANIELA ISLAS-MUÑOZ
BEDA DANIELA ISLAS-MUÑOZ
CFCynthia Pamela Alatorre Fernández
Cynthia Pamela Alatorre Fernández
CCCyntia Ibanes-Gutiérrez C
Cyntia Ibanes-Gutiérrez C
PVPatricia Volkow
Patricia Volkow
PJPatricia Cornejo Juarez
Patricia Cornejo Juarez

16 July 2025 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
PVPatricia Volkow
Patricia Volkow
SPSaraí Pineda-Benitez
Saraí Pineda-Benitez
CFCynthia Pamela Alatorre Fernández
Cynthia Pamela Alatorre Fernández
BIBEDA DANIELA ISLAS-MUÑOZ
BEDA DANIELA ISLAS-MUÑOZ
CVConsuelo Velázquez-Acosta
Consuelo Velázquez-Acosta
PJPatricia Cornejo Juarez
Patricia Cornejo Juarez

1 July 2026 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
RBRodrigo Ville Benavides
Rodrigo Ville Benavides
HRHéctor Rivera-Villegas
Héctor Rivera-Villegas
OOObed Ocampo-Valdez
Obed Ocampo-Valdez
RFRafael Franco-Cendejas
Rafael Franco-Cendejas
JAJaime F. Andrade-Villanueva
Jaime F. Andrade-Villanueva
BCBrenda Crabtree-Ramírez
Brenda Crabtree-Ramírez
Background: Neurosyphilis, ocular syphilis, and otosyphilis occur more frequently among people with HIV-1 and are associated with higher morbidity and treatment failure. Intravenous penicillin G remains the standard therapy but requires hospitalization or prolonged intravenous access, creating barriers that are amplified in resource-limited settings facing recurrent penicillin shortages. Ceftriaxone is a potential alternative; however, comparative data in people with HIV are limited. Methods: We conducted a multicenter retrospective cohort study of adults with HIV at 5 public hospitals and 2 outpatient HIV clinics in Mexico (2015–2024). Participants had confirmed neurosyphilis, ocular syphilis, or otosyphilis. Participants received intravenous penicillin G (18–24 million IU/day) or ceftriaxone (1–2 g/day) for 10–14 days. The primary outcome was early serological response (ESR), defined as a ≥4-fold nontreponemal titer decline or seroreversion at 6 months. We performed 1:1 propensity score matching (39 pairs, n = 78), followed by logistic regression in the matched cohort. Results: Of 143 participants, 104 (73%) received intravenous penicillin G and 39 (27%) ceftriaxone. In the matched cohort, ESR occurred in 74.4% of penicillin-treated participants and 71.8% of ceftriaxone-treated participants (odds ratio 0.88, 95% confidence interval .32–2.40; P = .80). The results were consistent across all prespecified sensitivity analyses. Conclusions: In this multicenter cohort of people with HIV diagnosed with neurosyphilis, ocular syphilis, or otosyphilis, ceftriaxone showed comparable ESR to intravenous penicillin G. These findings support ceftriaxone as a reasonable alternative when standard therapy is limited by penicillin shortages, limited inpatient capacity, or financial constraints.